東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Magnetic resonance imaging biomarker...

Stephen, Renu M.

Linked to FindBook

Google Book

Amazon

博客來

Magnetic resonance imaging biomarkers for targeted cancer therapies.

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Magnetic resonance imaging biomarkers for targeted cancer therapies./
Author:	Stephen, Renu M.
Description:	189 p.
Notes:	Adviser: Robert J. Gillies.
Contained By:	Dissertation Abstracts International69-02B.
Subject:	Health Sciences, Oncology. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3297191
ISBN:	9780549449720

Magnetic resonance imaging biomarkers for targeted cancer therapies.
Stephen, Renu M.

Magnetic resonance imaging biomarkers for targeted cancer therapies. - 189 p.

Adviser: Robert J. Gillies.

Thesis (Ph.D.)--The University of Arizona, 2008.

In 2007, there will be an estimated 178,480 new cases of breast cancer diagnosed in women in the United States. The elucidation of the vast heterogeneity of individual tumors has led to a paradigm shift from a one-size fits all treatment strategy to more individualized treatment based on the molecular profile of the tumor. Identifying biomarkers that respond to or predict the action of drugs is important in identifying efficacious targets and drugs that will improve clinical outcome. To examine this, we first identified two breast cancer cell lines (ACC-3199 and ACC-3171) from a panel of low passage breast cells lines that were capable of growing serially as tumor xenografts. This was followed by the in vivo molecular characterization of these two cell lines. In ACC-3199 tumors, we identified a gain of pAKT expression compared to cultured cells. Based on this finding, we investigated the role of diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) as potential imaging biomarkers in identifying early response to PX-866, a PI3K inhibitor, in ACC-3199 tumors as represented by changes in tumor cellularity and hemodynamic parameters, respectively. Our results indicated that DW-MRI was able to identify an early response to PX-886 in ACC-3199 tumors as defined by an increase in the apparent diffusion coefficient (ADC) value of the tumors prior to changes in tumor volumes. Using DCE-MRI, we were able to conclude that PX-866 was not an effective anti-angiogenic agent as indicated by an increase in tumor permeability following therapy. Based on the VEGFR2 expression observed in ACC-3171 tumor xenografts, we examined the response of MDA-MB-231/GFP and ACC-3171 tumor xenografts to the anti-angiogenic agent, sunitinib, using the same imaging modalities. DW-MRI was able to detect increases in ADC values as early as 12 h post-treatment in both MDA-MB-231/GFP and ACC-3171 tumors. Thus, it appears that DW-MRI may be a useful clinical test in predicting the early response to PI3K and anti-angiogenic inhibitors. These imaging approaches, in addition to the further molecular characterization of breast tumors may lead to the improvement and development of medical therapies for breast cancer patients.

ISBN: 9780549449720Subjects--Topical Terms:

1018566
Health Sciences, Oncology.

Magnetic resonance imaging biomarkers for targeted cancer therapies.
LDR:03138nam 2200277 a 45 001 958845
005 20110704
008 110704s2008 ||||||||||||||||| ||eng d
020 $a 9780549449720
035 $a (UMI)AAI3297191
035 $a AAI3297191
040 $a UMI $c UMI
100 1 $a Stephen, Renu M. $3 1282304
245 1 0 $a Magnetic resonance imaging biomarkers for targeted cancer therapies.
300 $a 189 p.
500 $a Adviser: Robert J. Gillies.
500 $a Source: Dissertation Abstracts International, Volume: 69-02, Section: B, page: 0950.
502 $a Thesis (Ph.D.)--The University of Arizona, 2008.
520 $a In 2007, there will be an estimated 178,480 new cases of breast cancer diagnosed in women in the United States. The elucidation of the vast heterogeneity of individual tumors has led to a paradigm shift from a one-size fits all treatment strategy to more individualized treatment based on the molecular profile of the tumor. Identifying biomarkers that respond to or predict the action of drugs is important in identifying efficacious targets and drugs that will improve clinical outcome. To examine this, we first identified two breast cancer cell lines (ACC-3199 and ACC-3171) from a panel of low passage breast cells lines that were capable of growing serially as tumor xenografts. This was followed by the in vivo molecular characterization of these two cell lines. In ACC-3199 tumors, we identified a gain of pAKT expression compared to cultured cells. Based on this finding, we investigated the role of diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) as potential imaging biomarkers in identifying early response to PX-866, a PI3K inhibitor, in ACC-3199 tumors as represented by changes in tumor cellularity and hemodynamic parameters, respectively. Our results indicated that DW-MRI was able to identify an early response to PX-886 in ACC-3199 tumors as defined by an increase in the apparent diffusion coefficient (ADC) value of the tumors prior to changes in tumor volumes. Using DCE-MRI, we were able to conclude that PX-866 was not an effective anti-angiogenic agent as indicated by an increase in tumor permeability following therapy. Based on the VEGFR2 expression observed in ACC-3171 tumor xenografts, we examined the response of MDA-MB-231/GFP and ACC-3171 tumor xenografts to the anti-angiogenic agent, sunitinib, using the same imaging modalities. DW-MRI was able to detect increases in ADC values as early as 12 h post-treatment in both MDA-MB-231/GFP and ACC-3171 tumors. Thus, it appears that DW-MRI may be a useful clinical test in predicting the early response to PI3K and anti-angiogenic inhibitors. These imaging approaches, in addition to the further molecular characterization of breast tumors may lead to the improvement and development of medical therapies for breast cancer patients.
590 $a School code: 0009.
650 4 $a Health Sciences, Oncology. $3 1018566
650 4 $a Health Sciences, Radiology. $3 1019076
690 $a 0574
690 $a 0992
710 2 $a The University of Arizona. $b Nutritional Sciences. $3 1282305
773 0 $t Dissertation Abstracts International $g 69-02B.
790 $a 0009
790 1 0 $a Gillies, Robert J., $e advisor
791 $a Ph.D.
792 $a 2008
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3297191